Matches in SemOpenAlex for { <https://semopenalex.org/work/W3179323507> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W3179323507 endingPage "574.e1" @default.
- W3179323507 startingPage "568" @default.
- W3179323507 abstract "The safety and efficacy of subcutaneous immune globulin 20% (human) solution (Cuvitru; Ig20Gly) for primary immunodeficiency disease (PID) have been demonstrated in 2 pivotal trials.To describe patient characteristics and infusion parameters of patients with PID initiating Ig20Gly outside of a clinical trial setting.This retrospective, observational study analyzed records of patients participating in the HelloCuvitru program, a patient support program in the United States providing Ig20Gly free of charge for the first 4 infusions to patients aged 2 years or older who had PID and no previous experience of Ig20Gly. Data were collected retrospectively from patient records and during nurse visits.A total of 817 patients (88% of 931 enrolled) completed 4 infusions. At the fourth Ig20Gly infusion, the median (interquartile range) dose was 0.55 (0.46-0.69) g/kg/mo, infusion rate per site was 40 (30.0-50.0) mL, and infusion rate per site was 47 (42.5-53.3) mL/h/site. By the fourth infusion, most patients (58%) received Ig20Gly at 2 infusion sites every 7 (30%) or 14 (25%) days. Median prescribed Ig20Gly dose per month was similar across age groups; median infusion volume per site increased with age. Most patients younger than 18 years received infusions every 14 days; patients aged 18 years or older were more likely to receive infusions weekly. Infusion parameters were similar regardless of whether patients received previous immunoglobulin subcutaneously or intravenously.In this large, real-world population of patients with PID, most Ig20Gly infusions were administered for less than 1 hour and required fewer than 2 infusion sites, consistent with the pivotal trials. Infusion rate per site was similar regardless of age, previous immunoglobulin treatment, or infusion frequency." @default.
- W3179323507 created "2021-07-19" @default.
- W3179323507 creator A5040680224 @default.
- W3179323507 creator A5051646718 @default.
- W3179323507 creator A5061918372 @default.
- W3179323507 creator A5083479584 @default.
- W3179323507 creator A5085150364 @default.
- W3179323507 date "2021-11-01" @default.
- W3179323507 modified "2023-10-05" @default.
- W3179323507 title "Infusion parameters of 20% subcutaneous immunoglobulin for primary immunodeficiency diseases among patient support program participants" @default.
- W3179323507 cites W2012579017 @default.
- W3179323507 cites W2015644310 @default.
- W3179323507 cites W2511870232 @default.
- W3179323507 cites W2519097826 @default.
- W3179323507 cites W2567251402 @default.
- W3179323507 cites W3000301584 @default.
- W3179323507 doi "https://doi.org/10.1016/j.anai.2021.06.023" @default.
- W3179323507 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34224864" @default.
- W3179323507 hasPublicationYear "2021" @default.
- W3179323507 type Work @default.
- W3179323507 sameAs 3179323507 @default.
- W3179323507 citedByCount "4" @default.
- W3179323507 countsByYear W31793235072022 @default.
- W3179323507 countsByYear W31793235072023 @default.
- W3179323507 crossrefType "journal-article" @default.
- W3179323507 hasAuthorship W3179323507A5040680224 @default.
- W3179323507 hasAuthorship W3179323507A5051646718 @default.
- W3179323507 hasAuthorship W3179323507A5061918372 @default.
- W3179323507 hasAuthorship W3179323507A5083479584 @default.
- W3179323507 hasAuthorship W3179323507A5085150364 @default.
- W3179323507 hasBestOaLocation W31793235071 @default.
- W3179323507 hasConcept C119060515 @default.
- W3179323507 hasConcept C126322002 @default.
- W3179323507 hasConcept C167135981 @default.
- W3179323507 hasConcept C187212893 @default.
- W3179323507 hasConcept C2779019163 @default.
- W3179323507 hasConcept C2779134260 @default.
- W3179323507 hasConcept C2908647359 @default.
- W3179323507 hasConcept C71924100 @default.
- W3179323507 hasConcept C99454951 @default.
- W3179323507 hasConceptScore W3179323507C119060515 @default.
- W3179323507 hasConceptScore W3179323507C126322002 @default.
- W3179323507 hasConceptScore W3179323507C167135981 @default.
- W3179323507 hasConceptScore W3179323507C187212893 @default.
- W3179323507 hasConceptScore W3179323507C2779019163 @default.
- W3179323507 hasConceptScore W3179323507C2779134260 @default.
- W3179323507 hasConceptScore W3179323507C2908647359 @default.
- W3179323507 hasConceptScore W3179323507C71924100 @default.
- W3179323507 hasConceptScore W3179323507C99454951 @default.
- W3179323507 hasIssue "5" @default.
- W3179323507 hasLocation W31793235071 @default.
- W3179323507 hasLocation W31793235072 @default.
- W3179323507 hasOpenAccess W3179323507 @default.
- W3179323507 hasPrimaryLocation W31793235071 @default.
- W3179323507 hasRelatedWork W2061253854 @default.
- W3179323507 hasRelatedWork W2105151527 @default.
- W3179323507 hasRelatedWork W2971392718 @default.
- W3179323507 hasRelatedWork W3013145321 @default.
- W3179323507 hasRelatedWork W3037686638 @default.
- W3179323507 hasRelatedWork W3095141535 @default.
- W3179323507 hasRelatedWork W3162511055 @default.
- W3179323507 hasRelatedWork W3208090289 @default.
- W3179323507 hasRelatedWork W3210359220 @default.
- W3179323507 hasRelatedWork W4255376461 @default.
- W3179323507 hasVolume "127" @default.
- W3179323507 isParatext "false" @default.
- W3179323507 isRetracted "false" @default.
- W3179323507 magId "3179323507" @default.
- W3179323507 workType "article" @default.